Literature DB >> 15858397

Therapeutic considerations in the African-American patient with hypertension: considerations with calcium channel blocker therapy.

John M Flack1, Domenic A Sica.   

Abstract

African Americans have a higher prevalence, earlier onset, and more rapid progression of hypertensive end-organ disease, as well as excessive hypertensive mortality compared with other racial/ethnic groups. Most differences in hypertension and pressure-related complications between African Americans and whites appear to be quantitative and not qualitative. Improving the diagnosis, treatment, and control of hypertension in this highly vulnerable population is a major health care goal for the new millennium. In this regard the dietary pattern to be promoted for reduction of hypertension risk in African Americans is one of increased consumption of dairy products, fruit, and vegetables as well as a continued emphasis on decreased Na+ intake. When pharmacologic therapy is considered, multi-drug approaches are generally required, with diuretics, angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers), and calcium channel blocker therapy as oft-selected components of most such treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858397      PMCID: PMC8109431          DOI: 10.1111/j.1524-6175.2006.04475.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  30 in total

1.  Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.

Authors:  Janice G Douglas; George L Bakris; Murray Epstein; Keith C Ferdinand; Carlos Ferrario; John M Flack; Kenneth A Jamerson; Wendell E Jones; Julian Haywood; Randall Maxey; Elizabeth O Ofili; Elijah Saunders; Ernesto L Schiffrin; Domenic A Sica; James R Sowers; Donald G Vidt
Journal:  Arch Intern Med       Date:  2003-03-10

2.  Hypertension in special populations.

Authors:  John M Flack; Rosalind Peters; Vishal C Mehra; Samar A Nasser
Journal:  Curr Probl Cardiol       Date:  2003-02       Impact factor: 5.200

Review 3.  Differences in blacks and whites with essential hypertension: biochemistry and endocrine. State of the art lecture.

Authors:  B Falkner
Journal:  Hypertension       Date:  1990-06       Impact factor: 10.190

4.  Normotensive salt sensitivity: effects of race and dietary potassium.

Authors:  R C Morris; A Sebastian; A Forman; M Tanaka; O Schmidlin
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

5.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials.

Authors:  P K Whelton; J He; J A Cutler; F L Brancati; L J Appel; D Follmann; M J Klag
Journal:  JAMA       Date:  1997-05-28       Impact factor: 56.272

Review 7.  Role of dietary factors in the hypertension of African Americans.

Authors:  H J Adrogué; D E Wesson
Journal:  Semin Nephrol       Date:  1996-03       Impact factor: 5.299

8.  Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial.

Authors:  L P Svetkey; D Simons-Morton; W M Vollmer; L J Appel; P R Conlin; D H Ryan; J Ard; B M Kennedy
Journal:  Arch Intern Med       Date:  1999-02-08

9.  Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  B J Materson; D J Reda; W C Cushman
Journal:  Am J Hypertens       Date:  1995-02       Impact factor: 2.689

10.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

View more
  4 in total

1.  The evolving clinical management of hypertension.

Authors:  Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-11-10       Impact factor: 3.738

2.  Treatment of hypertension among African Americans: the Jackson Heart Study.

Authors:  Jane Harman; Evelyn R Walker; Vicki Charbonneau; Ermeg L Akylbekova; Cheryl Nelson; Sharon B Wyatt
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-01       Impact factor: 3.738

3.  Adherence treatment factors in hypertensive African American women.

Authors:  Marie N Fongwa; Lorraines S Evangelista; Ron D Hays; David S Martins; David Elashoff; Marie J Cowan; Donald E Morisky
Journal:  Vasc Health Risk Manag       Date:  2008

4.  Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy.

Authors:  Shawna Nesbitt; Ali Shojaee; Jen-Fue Maa
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-01       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.